Medical Billing · Nationwide
Pediatric Targeted Radioiodine & MIBG Therapy for Neuroblastoma Medical Billing Services
High-dose targeted radionuclide therapy for high-risk refractory neuroblastoma and pheochromocytoma: therapeutic Iodine-131 metaiodobenzylguanidine (I-131 MIBG 79445), radiation dosimetry calculations (78804/78830), medical radiation physics (+77336), lead-lined isolation room inpatient admissions, stem cell rescue support (+38240), and radioisotope pass-through invoice recovery (HCPCS A9508).
Aethera Healthcare Solutions provides full-service medical billing and revenue cycle management to pediatric nuclear medicine oncologists, radiation oncologists, pediatric hematologist-oncologists, and tertiary pediatric cancer centers across the United States. We handle coding, claims, payment posting, denial management, and A/R follow-up end to end — so your team can stay focused on patient care while your revenue cycle runs cleanly.
Typical pediatric targeted radioiodine & mibg therapy for neuroblastoma CPT range we work: 79445, 79101, 78804, 78830, 77300, 77336, 38240, A9508, 99223, 99233.
Why pediatric targeted radioiodine & mibg therapy for neuroblastoma billing leaks revenue
Radiopharmaceutical pass-through invoice (A9508) disallowance: Payers refusing to reimburse $35,000–$60,000 high-dose I-131 MIBG isotope costs under generic DRG carve-out rules
Radiation physics consultation (+77336) and dosimetry bundling: Commercial payers rejecting mandatory medical physicist dose calculations and radiation protection protocols
Lead-lined radiation isolation inpatient stay downcoding: Denial of specialized inpatient safety isolation room per diem charges during prolonged radioactive clearance
Autologous hematopoietic stem cell rescue (+38240) denial: Clearinghouse disputes when post-MIBG myelosuppression necessitates delayed stem cell reinfusion
How Aethera fixes it
Specialty-trained coders (CPC/CCS) code to the documentation
First-pass claim scrubbing against payer and NCCI edits
Proactive denial prevention and 72-hour denial work
Relentless A/R follow-up to drive days-in-A/R down
Eligibility and prior-auth verification before service
Transparent, real-time reporting in the provider portal
Free tools for your billing team
Use these any time — no login required.
Pediatric Targeted Radioiodine & MIBG Therapy for Neuroblastoma billing FAQ
How is therapeutic high-dose I-131 MIBG administration reported for pediatric neuroblastoma?
Therapeutic administration of radiopharmaceuticals for non-thyroid malignancy (specifically I-131 MIBG for neuroblastoma) is coded using CPT 79445 (radiopharmaceutical therapy, by intravenous infusion). The therapeutic radionuclide itself is separately billed using HCPCS A9508 (iodine I-131 iobenguane, therapeutic, per millicurie) with itemized pharmacy invoices and exact millicurie dose administered. Concurrent medical physicist radiation protection and continuous survey monitoring is reported using CPT +77336.
Can radiation dosimetry and physics consultation (+77336) be billed during inpatient MIBG therapy?
Yes. Due to extreme radiation exposure hazards associated with therapeutic I-131 activities (often exceeding 12–18 mCi/kg in pediatric patients), continuous medical physics oversight is a statutory Nuclear Regulatory Commission (NRC) mandate. CPT 77336 (continuing medical physics consultation, including radiation dose verification) and CPT 78830 (whole body SPECT/CT radiopharmaceutical localization and clearance dosimetry) are separately reimbursable with appropriate clinical physicist reports.